ALK1 loss results in vascular hyperplasia in mice and humans through PI3-kinase activation

Elisenda Alsina-Sanchís¹,²,Δ, Yaiza García-Ibáñez¹,²,Δ, Ana M. Figueiredo¹,³, Carla Riera-Domingo¹,², Agnès Figueras¹,², Xavier Matias-Guiu²,⁴,⁵,⁶, Oriol Casanovas¹,², Luisa M. Botella⁷, Miquel A. Pujana¹,², Antoni Riera-Mestre⁸,⁹, Mariona Graupera¹,³,¹⁰,¹²* & Francesc Viñals¹,²,¹¹,¹²*

1 Program Against Cancer Therapeutic Resistance (ProCURE), Institut Català d’Oncologia (ICO), Hospital Duran i Reynals, Gran Via 199-203, 08907 L’Hospitalet de Llobregat (Barcelona), Spain; 2 Institut d’Investigació Biomèdica de Bellvitge (IDIBELL); 3 Vascular Signaling Laboratory, Institut d’Investigació Biomèdica de Bellvitge (IDIBELL), Gran Via 199-203, 08908 L’Hospitalet de Llobregat, Spain; 4 Servei d’Anatomia Patològica, Hospital Universitari de Bellvitge-IDIBELL; 5 Hospital Universitari Arnau de Vilanova, Lleida, Spain; 6 Universitat de Lleida; 7 Centro de Investigaciones Biológicas, Consejo Superior de Investigaciones Científicas (CSIC), Madrid, Spain; 8 HHT Unit, Internal Medicine Department, Hospital Universitari de Bellvitge-IDIBELL; 9 Departament de Ciències Clíniques, Facultat de Medicina, Universitat de Barcelona; 10 CIBERONC; 11 Departament de Ciències...
Fisiològiques, Campus de Bellvitge, Universitat de Barcelona, Avda. Feixa Llarga s/n, 08907 L’Hospitalet de Llobregat (Barcelona), Spain.

Δ Equal contribution

12 Joint last authors

Running title: PI3K inhibitors to treat HHT2 patients

* To whom correspondence should be addressed.

Mailing address: Dr. Francesc Viñals - Program Against Cancer Therapeutic Resistance (ProCURE), Institut Català d’Oncologia – IDIBELL, Hospital Duran i Reynals, Gran Via 199-203, 08908 L’Hospitalet de Llobregat, Barcelona, Spain. E-mail: fvinyals@iconcologia.net; Dr. Mariona Graupera: Vascular Signaling Laboratory, IDIBELL, Hospital Duran i Reynals, Gran Via 199-203, 08908 L’Hospitalet de Llobregat, Barcelona, Spain. E-mail: mgraupera@idibell.cat.

Keywords: PI3K, HHT, ALK1, BMP9, PTEN

Subject codes: Angiogenesis, Cell Signaling/Signal Transduction, Vascular Biology, Vascular Disease

Word count: 6441 words
Figures: 6

Tables: 1

TOC category: Translational

TOC subcategory: Vascular Biology
ABSTRACT

Objective: Activin-receptor like kinase 1 (ALK1) is an endothelial cell-restricted receptor with high affinity for bone morphogenetic protein 9 (BMP9) Transforming growth factor β (TGFβ) family member. Loss of function mutations in ALK1 cause a subtype of Hereditary Hemorrhagic Telangiectasia (HHT), a rare disease characterized by vasculature malformations. Therapeutic strategies are aimed at reducing potential complications due to vascular malformations, but there is no currently a curative treatment for HHT.

Approach and Results: In this work, we report that a reduction in ALK1 gene dosage (heterozygous ALK1+/- mice) results in enhanced retinal endothelial cell proliferation and vascular hyperplasia at the sprouting front. We found that BMP9/ALK1 represses VEGF-mediated phosphatidylinositol 3-kinase (PI3K) by promoting the activity of the phosphatase and tensin homolog (PTEN). Consequently loss of ALK1 function in endothelial cells results in increased activity of the PI3K pathway. These results were confirmed in cutaneous telangiectasia biopsies of HHT2 patients, in which we also detected an increase in endothelial cell proliferation linked to an increase on the PI3K pathway. In mice, genetic and pharmacological inhibition of PI3K is sufficient to abolish the vascular hyperplasia of ALK1+/- retinas and in turn normalize the vasculature.

Conclusions: Overall, our results indicate that the BMP9/ALK1 hub critically mediates vascular quiescence by limiting PI3K signaling and suggest that PI3K inhibitors could be used as novel therapeutic agents to treat HHT.
Non-standard Abbreviations and Acronyms

ALK1: Activin-receptor like kinase 1
BMP: bone morphogenetic proteins
ERK: extracellular signal-regulated kinases
FGF: fibroblast growth factor
HHT: Hereditary Hemorrhagic Telangiectasia
PI3K: phosphatidylinositol 3-kinase
PTEN: phosphatase and tensin homolog
TGFβ: Transforming growth factor β
VEGF: Vascular Endothelial Growth Factor
INTRODUCTION

Blood vessels play essential roles in the transport of gases, nutrients, waste products and circulating cells in the healthy organism. While vessels are quiescent in adults, the growth of blood vessels is critical to development, growth and regeneration \(^1, 2\). Angiogenesis, the formation of new blood vessels, consists of sprouting new vessels from pre-existing ones and the eventual fusion of these with other sprouts or blood vessels to form new vascular connections. Vessel growth is stimulated by angiogenic factors, which are divided into: (1) activators, such as vascular endothelial growth factor-A (VEGF-A, hereafter referred to as VEGF), fibroblast growth factor 2 (FGF-2), and epidermal growth factor (EGF), which induce endothelial cell proliferation and migration \(^1, 3\); and (2) maturation factors, such as tumor necrosis factor-\(\alpha\) (TNF-\(\alpha\)), interleukin-8 (IL-8) and some members of the transforming growth factor (TGF) \(\beta\) family, which prompt endothelial cells to cease proliferation, reestablish basal membrane, and recruit mural cells \(^4, 5\). Bone morphogenetic protein 9 (BMP9) is a member of the TGF-\(\beta\) family that selectively activates activin-receptor like kinase (ALK) 1, a serine-threonine kinase type I TGF-\(\beta\) receptor in endothelial cells \(^6\). Activation of ALK1 triggers the phosphorylation of Smad 1, 5 and 8, which in turn form an active complex with Smad4, translocate to the nucleus, and stimulate the expression of genes such as inhibitors of differentiation (IDs), endoglin and Tmem100 \(^7-9\). BMP9 has been proposed as limiting VEGF and FGF-induced endothelial cell proliferation \(^6, 10, 11\). However, it is still unclear how ALK1 negatively regulates proangiogenic cascades. Given the inhibitory role of ALK1 during vessel growth, it is not surprising that genetic and pharmacological blockage of ALK1 \(in vivo\) results in aberrant overgrowth of the vasculature \(^12, 13\).
Hereditary hemorrhagic telangiectasia (HHT), also known as Rendu-Osler-Weber syndrome, is a rare autosomal-dominant germline disease, with an incidence of 1:5,000, characterized by the local overgrowth of the vascular plexus. The telangiectasia is the common name for vascular lesions in HHT patients, and consists of an artery directly connected to a vein that generates a fragile site that can easily rupture and bleed. The telangiectasias are found on the skin of the face and hands, and the lining of the nose and mouth. Less common, but more severe, are the internal vascular lesions, which principally occur in lung, liver and the digestive tract, and may lead to hemorrhagic episodes, stroke or brain abscesses secondary to pulmonary arteriovenous malformations (AVMs); or arterial aneurysms and pulmonary arterial hypertension, or high-output heart failure secondary to liver vascular malformations. HHT is divided into HHT types 1 and 2 on the basis of the mutation responsible for the pathogenesis of the disease. While HHT1 arises from inactivation mutations in ENG, the gene encoding the TGF-β co-receptor endoglin, HHT2 is caused by mutations in ACVRL1, the gene encoding ALK1. Pulmonary and cerebral arteriovenous malformations are more common in HHT1, while hepatic vascular malformations predominate in HHT2. Therapeutic strategies are aimed at reducing potential complications due to vascular malformations, but there is currently no curative treatment for HHT.

In this study we used heterozygous ALK1 mouse retinas and cultured endothelial cells to study how ALK1 represses vessel growth. We found that loss of ALK1 leads to increased stalk cell proliferation as a result of overactivation of PI3K signaling. By analyzing a small cohort of patients, we found that mutations in ALK1 result in increased activation of PI3K signaling in human telangiectasias compared with control vessels. These findings, together with the observation that blocking the
PI3K signaling pathway rescues ALK1-induced vascular hyperplasia, provide the proof of concept for therapeutic intervention with PI3K inhibitors for the treatment of HHT.

MATERIALS AND METHODS

Materials and Methods are available in the online-only Data Supplement.

RESULTS

Heterozygous loss of ALK1 results in retinal vascular hyperplasia

To gain insight into the molecular mechanism accounting for vascular malformations upon loss of ALK1 function in HHTs patients, we investigated vessel growth in postnatal mouse retinas. $ALK1^{+/−}$ mice die in midgestation $^{12, 13}$, so we studied heterozygous $ALK1^{+/−}$ retinas. Whole-mount isolectin B4 (IB4)-stained $ALK1^{+/−}$ retinas showed no differences in vascular radial expansion or the number of branch points compared with wild-type littermates’ retinas at postnatal days 5 (P5), P7 and P9 (Fig. 1 and Suppl. Fig. 1). In contrast, a partial decrease in ALK1 levels resulted in vessel hyperplasia, as indicated by increased vessel width (Fig. 1). Vessel hyperplasia in $ALK1^{+/−}$ retinas occurred in capillary areas located above veins at P5, P7 and P9, whereas the effect was only observed in capillary areas located above arteries at P9 (Fig. 1). Together, these findings indicate that ALK1 signaling limits vessel width in sprouting angiogenesis but it is not necessary for EC migration and til/stalk election. Although $ALK1^{+/−}$ retinas have a mild vascular phenotype, they partially recapitulate
the phenotype of full inactivation of ALK1 in endothelial cells \(^9\), demonstrating a
dose-response effect of ALK1 in endothelial cells.

Coverage by mural cells regulates vessel diameter. Hence, the increase in
vessel width induced by ALK1 inhibition could be a consequence of reduced coverage
by mural cells \(^{20, 21}\). However, immunostaining with desmin, a marker for retinal
pericytes, did not reveal any obvious difference between wild-type and \(ALK1^{+/−}\) retinas
(Suppl. Fig. 2). Next, we examined whether an increase in endothelial cell number
could account for the increase in vessel width upon heterozygous loss of \(ALK1\). To
this end, wild-type and \(ALK1^{+/−}\) retinas were stained with Erg-1/2/3, an endothelial-
specific nuclear marker. Surprisingly, no differences were observed in the frequency
of endothelial cells located in the inner retinal zone or in the first migratory endothelial
cell line (mainly tip cells) \(^{22}\) (Fig. 2A and B). Conversely, an accumulation of 25%
more endothelial cells were observed in the sub-front (mainly formed of stalk cells) of
\(ALK1^{+/−}\) retinas compared with wild-type retinas. To establish whether this greater
number was caused by an increase in endothelial cell proliferation, retinas were co-
stained with Erg-1/2/3 and Edu (a proliferation marker) (Fig. 2A and C). Consistently,
no differences were observed in the number of proliferative endothelial cells located in
the internal vascular retinal area and in the first migratory endothelial line. Instead, a
41% higher frequency of proliferative endothelial cells was observed in the sub-front
of \(ALK1^{+/−}\) retinas, indicating that ALK1 signaling restricts endothelial cell
proliferation \textit{in vivo} at the sprouting front.
BMP9 blocks VEGF-induced proliferation in HUVECs

To understand the mechanisms by which ALK1 prevents cell cycle progression in endothelial cells, we used cultured human umbilical vein endothelial cells (HUVECs) and studied the crosstalk between BMP9 and angiogenic signals such as VEGF. First, we stimulated HUVECs with VEGF, BMP9 or a combination of both, for 48 h or 72 h, followed by assessment of the total number of cells. While BMP9 alone did not change the growth of HUVECs, VEGF promoted a 37% increase in cell number after 48 h and a 326% after 72 h (Fig. 2D). However, VEGF failed to stimulate cell number in the presence of BMP9. To confirm that BMP9 blocks cell proliferation without stimulating cell death, we measured BrdU incorporation in quiescent HUVECs in the presence of BMP9 and VEGF. As expected, stimulation with VEGF led to a greater degree of BrdU incorporation in HUVECs (Fig. 2E) compared with non-stimulated conditions. We also found that BrdU incorporation was reduced by BMP9 stimulation in basal and VEGF-stimulated cells. BMP9 addition also reduced cell proliferation in complete medium (20% FCS). In agreement with the negative BMP9-ALK1 role, addition of LDN-212854, an ALK1 inhibitor increased BrdU incorporation in HUVEC alone and reverted the inhibition caused by BMP9 (Fig. 2E).

BMP9 dampens VEGF-induced activation of AKT and ERKs

Next, we analyzed the effect of 15 min or 4 h BMP9 pretreatment in VEGF-mediated activation of PI3K-AKT, ERK1/2 and p38. We used phosphoSMAD1/5 and total abundance of ID1 as readout of BMP9/ALK1 signaling (Fig. 3, Suppl. Fig. 3 and
Suppl. Fig. 4). Stimulation with VEGF for 10 and 30 min triggered the phosphorylation of AKT and ERK1/2. VEGF and BMP9 both stimulated p38 MAPK phosphorylation, with a synergistic effect upon incubation when both were used (Fig. 3 and Suppl. Fig. 4). Pretreatment with BMP9 for 15 min before VEGF incubation had no effect on AKT and ERK1/2 activation (Suppl. Fig. 4A). Instead, a 4-h preincubation with BMP9 blocked basal and VEGF-mediated phosphorylation of AKT (in Threonine 308 and Serine 473) and ERK1/2, without affecting total amount of AKT or ERK1/2 protein or phosphorylation of VEGFR2 (Fig. 3). This effect was dose-dependent, with a maximum effect achieved at a dose of 0.5 ng/ml of BMP9 in the absence of VEGF and of 5 ng/ml in the presence of VEGF (Suppl. Fig. 4C-E). Moreover, a minimum of 2 h time of preincubation with BMP9 was necessary to overrule the VEGF mediated activation of AKT and ERKs (Suppl. Fig. 4). We then sought to determine whether preincubation with VEGF also impaired the BMP9 canonical signaling pathway. However BMP9-induced phosphoSMAD1/5 and ID1 expression were not altered if the cells had been preincubated with VEGF for 1 h before adding BMP9 (Suppl. Fig. 5). Taken together, our data findings indicate that BMP9/ALK1 fine-tunes VEGF signaling, but this pro-angiogenic cue has no effect in modulating BMP9 signaling. Our results identify BMP9 as a negative modulator of proangiogenic signals in endothelial cells.

**BMP9 inhibits PI3K signaling by increasing PTEN activity**

The PI3K/PTEN axis \(^{22, 23}\), but not ERK1/2 signaling \(^{24}\), has been shown to regulate endothelial cell proliferation in mouse retina angiogenesis. Furthermore, loss of PTEN in endothelial cells results in vascular hyperplasia similar to that observed in
Therefore, we hypothesized that BMP9 fine-tunes PI3K signaling by regulating PTEN. To confirm this we first measured PTEN phosphatase activity. PTEN was immunoprecipitated from endothelial cells treated or not with BMP9 for 4 h and additional 30 min with VEGF, and PTEN activity was quantified by its capacity to dephosphorylate Pi(3,4,5)P3 to Pi(4,5)P2. BMP9 treatment promoted a 48% increase in PTEN phosphatase activity, and this effect was independent of the presence or not of VEGF (Fig. 4A). Next we measured protein abundance after BMP9 treatment. Our results showed that PTEN amount were maintained by a 4-h treatment with BMP9 but increased substantially (86%) when cells were treated with BMP9 for 24 h (Fig. 4B and Suppl. Fig. 6A). This effect was correlated with an increase in PTEN mRNA abundance induced by BMP9 (44% after 4 h and 184% after 24 h of BMP9 treatment) (Fig. 4C). To confirm that PTEN was important for the inhibitory effect of BMP9 on AKT, we blocked its expression in HUVECs by siRNA transfection. The siRNAs acting against PTEN reduced PTEN protein amount and led to hyperactivation of the PI3K/AKT pathway (Fig. 4D and Suppl. Fig. 6B). More importantly, PTEN depletion abolished the inhibitory effects of BMP9 on AKT phosphorylation in basal and VEGF-stimulated cells, confirming that PTEN plays a critical role in BMP9-induced repression of PI3K/AKT. Next we evaluated the effect of PTEN depletion on cell cycle progression in endothelial cells by assessment of the total number of cells. While VEGF failed to stimulate cell number in the presence of BMP9 in non silencing control cells, in the absence of PTEN BMP9 was not able to block VEGF-induced cell proliferation (Fig. 4E). We confirmed this result by incubating HUVEC with a PTEN inhibitor, SF1670. This compound also blocked the inhibitory effect of BMP9 on VEGF-induced endothelial cell number (Fig. 4F), further supporting that PTEN activity is necessary to mediate BMP9 effects.
Activation of the PI3K pathway in cutaneous telangiectasia biopsies of HHT2 patients

Having identified the mechanism of action of negative regulation by BMP9 signaling on pro-angiogenic signals, next we aimed to study the status of the PI3K pathway in samples from HHT2-affected individuals. To this end, we first examined publicly available gene expression data from nasal tissue of HHT2-affected and control individuals (21 and 19, respectively 25). Using a rank-based algorithm 26, a significant bias towards over-expression of genes linked to PI3K/AKT signaling (measured with three gene sets) was observed in telangiectasial tissue relative to normal tissue of HHT2 patients (\(P\) values < 0.01, Fig. 5A and Supplementary Table 1). Significant over-expression of these sets was also observed when comparing data of telangiectasial HHT2 tissue against normal tissue obtained from healthy individuals, but no when comparing normal HHT2 against normal tissue of healthy individuals 25.

Next, we analyzed cutaneous telangiectasia biopsies from six HHT2 patients with mutations in the \textit{ACVRL1} gene (Table 1) and from three controls. We performed immunohistochemistry for CD34 (an endothelial cell marker), pAKT (S473), pNDRG1 (Thr 346) and pS6 (S240/244) (markers of PI3K activation) 27, 28. As shown in Fig. 5B and C we found a 53% increase of vessels that were positive for pAKT. Moreover, a low frequency of control vessels were positive for pNDRG1 (3%) (Fig. 5B and D). In contrast, in the telangiectasia cohort we found a five-fold greater frequency of vessels that were positive for pNDRG1. Similarly, while endothelial cells from control biopsies were negative for pS6 staining, we found a seven-fold greater
frequency of endothelial cells that were positive for pS6 (Fig. 5B and E). Interestingly, we found a statistical significant positive correlation between grade of positivity for pNDRG1 and nosebleed severity measured by the Epistaxis Severity Score (Table 1 and Suppl. Fig. 7).

Patients with HHT present enlarged abnormal vessels with high number of endothelial cells (Fig. 5B). We asked whether mutations in ALK1 also increased endothelial cell proliferation in vessels from HHT2 patients, as observed in our mouse model. We performed immunohistochemistry for Ki67, a proliferation marker, in our HHT2 patient’s group and compare it with controls. Results indicated that the mean proliferation index was 3.3x significantly higher in endothelial cells from telangiectasias of HHT2 patients than in control vessels (2.3 versus 0.7, respectively) (Fig. 5B and F).

**Inhibition of PI3K prevents vascular hyperplasia induced by loss of ALK1 expression**

Finally, we examined whether inhibition of PI3K signaling can revert the vascular hyperplasia phenotype induced by heterozygous loss of ALK1 in vivo. To this end, we crossed ALK1+/− heterozygous animals with a constitutive mouse line in which endogenous p110α/PI3K isoform is converted into kinase-dead protein (hereafter p110α<sup>KD/WT</sup>). While homozygous p110α<sup>KD/KD</sup> mice die during embryonic development as a consequence of vascular failure, heterozygous inactivation of p110α results in mild reduction of radial expansion <sup>30</sup>, an effect that was maintained in double-heterozygous mutant retinas (ALK1<sup>+/−</sup>, p110α<sup>KD/WT</sup>), Suppl. Fig. 8). Instead,
reduced p110α activity rescued the hyperplasia induced by heterozygous loss of ALKI (Fig. 6A and B). We validated these results by pharmacological inhibition of PI3K signaling with LY294002, a pan-PI3K inhibitor. Pups were treated with LY294002 at P6 and P7 (Fig. 6C), and their retinal vasculature was examined at P7. The hyperplasia induced by ALKI heterozygosity was also rescued by pharmacological inhibition of PI3K activity (Fig. 6D and E). Taken together, these results confirm that BMP9/ALK1 regulates endothelial cell proliferation in vivo, at least partially, by inhibiting PI3K/AKT signaling.

DISCUSSION

In the present study we demonstrate that BMP9/ALK1 promotes vascular quiescence by inhibiting PI3K/AKT and ERK MAPK activation, and show that loss of ALK1 causes overstimulation of these signaling hubs. In recent years, the role of the BMP9-BMPRII-ALK1-endoglin-SMAD1/5 axis in endothelial cells has begun to be clarified. Indeed, BMP9/ALK1 inhibits cell proliferation and migration in cultured endothelial cells and in zebrafish. In mice, the blockade of BMP9/ALK1 signaling by anti-BMP9 neutralizing antibody or by injection of the extracellular domain of ALK1 increases vascular density. Also in mice, depletion of ALK1 specifically in endothelial cells results in arteriovenous malformations as a result of increased endothelial cell proliferation. Our results in vitro and in vivo confirm this anti-proliferative role of BMP9/ALK1 in sprouting angiogenesis. Our work also reveals that during vessel growth BMP9/ALK1 signaling does not regulate cell proliferation in all angiogenic endothelial cells in vivo but, rather, specifically in those cells located at the sprouting. Activation of Notch at the sprouting front results
in stalk cell cycle arrest through a similar mechanism to that of BMP9/ALK1 (see below). It is therefore reasonable to speculate that Notch and BMP9/ALK1 cooperate to restrain stalk cell proliferation at this specific location. In keeping with this, previous results have shown that ALK1, through SMAD1/5 or SMAD2/3 activation, cooperates with the Dll4/Notch pathway to induce the stalk cell phenotype.

Our and findings place PI3K/AKT and ERK MAPK at the center of the BMP9/ALK1 anti-proliferative response (Suppl. Fig. 9). Our results using HUVECs as a model have shown that BMP9/ALK1 blocks the PI3K/AKT and ERK activation induced by VEGF. In contrast, we have found that pharmacological inhibition of PI3K is sufficient to abolish ALK1-induced vascular hyperplasia . This observation, together with the fact that inhibitors of MEK1-ERKs in vivo fail to block endothelial cell proliferation in wild-type retinal angiogenesis, suggest that limiting PI3K signaling is the principal mechanism by which ALK1 stimulates vascular quiescence . The PI3K/AKT pathway stimulates cell proliferation, migration and survival in endothelial cells downstream of many angiogenic cues. We have identified BMP1/ALK1 as a new upstream signal that regulates PI3K activity in sprouting angiogenesis. While most of the angiogenic cues activate the PI3K signaling pathway to execute their biological actions, we have found that BMP9/ALK1 represses this signaling cascade by stimulating the activity of PTEN, the principal phosphatase that counteracts this signaling pathway in endothelial cells. PTEN is a lipid and protein phosphatase whose function is regulated at multiple levels, including mRNA and protein expression, subcellular localization, and direct regulation of its phosphatase activity by post-translational modifications such as phosphorylation, ubiquitination and protein interactions. We have identified that regulation of
PTEN by BMP9/ALK1 in endothelial cells is also multifactorial. First, the observation that BMP9/ALK1 dampens AKT phosphorylation after a 2-h incubation with BMP9 suggests a direct regulation of PTEN catalytic activity. Recently, Ola et al. have described that the phosphorylated Ser380/Thr382/Thr383-inactive form of PTEN was decreased in HUVECs and mLECs endothelial cells stimulated for 2 hours with BMP9. Second, we have clear evidence that stimulation of endothelial cells by BMP9/ALK1 increases mRNA and protein abundance of PTEN. This is not unique to BMP9/ALK1, as we have previously shown that Dll4/Notch also stimulates PTEN expression to block stalk cell proliferation. Given the previously identified crosstalk between ALK1 and Notch, the increase in PTEN amount upon BMP9 stimulation could be explained by an indirect response induced by Notch. However, we cannot rule out a direct effect of SMADs on PTEN promoter upon BMP9 stimulation. PTEN expression is also tightly regulated by miR, including in endothelial cells. Indeed, VEGF restrains PTEN expression amount by increasing the expression of the miR-17-92 cluster in endothelial cells. Therefore, it is also possible that BMP9/ALK1 regulates PTEN abundance by inhibiting negative regulators of its expression. Taken together, we have identified a previously unknown interaction of BMP9/ALK1 and PTEN in endothelial cells, which seems critical to the pathogenesis of loss of ALK1 expression.

HHT is mainly caused by heterozygous mutations in endoglin (ENG) or ALK1 (ACVRL1) genes. These are loss of function mutations that lead to reduced BMP9/ALK1/endoglin/SMAD1/5 signaling and enhanced response to angiogenic cues, and thereby to excessive abnormal angiogenesis. The telangiectasia arises from a postcapillary hyperplastic venule that fuses directly with an arteriole, resulting in an arteriovenous shunt in the small-sized vessels. The role of endothelial cell
proliferation in the development of these enlarged abnormal vessels in HHT has not been studied in depth. Hashimoto et al. found higher Ki-67 index for endothelial cells of sporadic brain AVMs compared with endothelial cells from control cortical vessels. In the case of HHT, Du et al. found increased endothelial cell proliferation in a resection of intracranial AVM in a 26-day-old boy with HHT. Our data obtained in patients, as well as the results obtained in mouse models, confirm that AVMs and increased endothelial cell proliferation are interrelated, suggesting that the AVM phenotype in HHT patients arises, at least in part, from an aberrant endothelial cells proliferation. In line with this stimulation of VEGF signaling, a promitogenic factor for endothelial cells, is required for the development of HHT. Indeed, although heterozygous ALK1 mice do not develop AVM, intracranial injection of VEGF in ALKI+/− mice leads to abnormal AVM-like structures, and blocking VEGF attenuates these vascular lesions. This is in agreement with the observation that PI3K/AKT is a key signaling hub downstream of VEGF in angiogenesis. Our results show for first time an overstimulation of the PI3K pathway on vessels of HHT2 patients. We found a statistically significant relationship between PI3K-activated vessels in the finger telangiectasia biopsy and the severity of nosebleeds measured by the Epistaxis Severity Score. This association suggests a more intense development of systemic telangiectasias (i.e., cutaneous or in nasal mucosa) when PI3K signaling is active. It is of particular note that we and others have found that the majority of venous malformations, the most common form of vascular malformation, are driven by constitutively activating PI3K signaling. Taken together, the results suggest that overactivation of PI3K signaling is a common characteristic in vascular malformations. By using a mouse model for HHT, our findings also show that the genetic or pharmacological inhibition of PI3K prevents ALK1-induced vascular
hyperplasia in retinas. Our findings corroborate results by Ola et al. 39 in which homozygous deletion of \textit{ALK1} in endothelial cells results in arterial venous shunts also by up regulating PI3K signaling. These results suggest that PI3K inhibitors could be used as an alternative therapeutic approach to treating HHT patients. Inhibition of the PI3K signaling in the vasculature could therefore prevent the development of telangiectasias and improve nose bleeds in HHT patients. In keeping with this observation, a study has reported a clinical case of an HHT2 patient diagnosed with serous ovarian cancer who showed a drop in the frequency of epistaxis upon treatment with a PI3K inhibitor (BKM120) 52. Therefore, we propose that the use of PI3K or AKT inhibitors should be considered as alternative pharmacological strategies for treating HHT patients.

ACKNOLEDGEMENTS

\textbf{Acknowledgements}: We thank K. Pietras (Lund University, Sweden) and S. Paul Oh (University of Florida, USA) for the \textit{ALK1} heterozygous animals. We are grateful to the subjects who participated in this study.

\textbf{Sources of funding}: This study was supported by research grants from the Spanish Ministerio de Economía y Competitividad (SAF2013-46063-R and SAF2017-85869-R) and the Generalitat de Catalunya (2014SGR364) to F.V. E.A. is a recipient of a predoctoral fellowship from the Ministerio de Economía y Competitividad. Work in M.G.’s laboratory is supported by research grants SAF2014-59950-P and SAF2017-89116-R from the Spanish Ministerio de Economía y Competitividad (Spain), 2014-SGR-725 from the Catalan Government, the People Programme (Marie Curie Actions; grant agreement 317250) of the European Union's Seventh Framework Programme
Disclosures: Unrestricted grant from Roche to finance the ProCure Programme, which was paid to the Catalan Institute of Oncology (2015).

REFERENCES


Highlights

- ALK1 receptor negatively regulates endothelial cell proliferation by repressing PI3K signaling through PTEN activation.
- Loss of ALK1 function in endothelial cells of HHT2 patients results in increased activation of PI3K signaling, enhanced endothelial cell proliferation, and in turn vascular hyperplasia.
- We have also found a correlation between PI3K-activated vessels in the telangiectasias and the severity of epistaxis.
- Genetic or pharmacological inhibition of PI3K is sufficient to abolish the vascular hyperplasia induced by heterozygous loss of ALK1 in mouse retinas, providing the proof of concept for therapeutic intervention with PI3K inhibitors for the treatment of HHT.
## TABLE 1. HHT2 patients characteristics

<table>
<thead>
<tr>
<th>No. Patient*</th>
<th>Age</th>
<th>M/F</th>
<th>Contrast TTE</th>
<th>Abdominal computed tomography</th>
<th>CI (L/min/m²)</th>
<th>ESS*</th>
<th>pNDRG1 vessels (%)</th>
<th>ACVRL1 mutations</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>62</td>
<td>F</td>
<td>1</td>
<td>Intrahepatic telangiectasias</td>
<td>3.74</td>
<td>2.83</td>
<td>8.4%</td>
<td>Exon 3:</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Hepatic AV shunt</td>
<td></td>
<td></td>
<td></td>
<td>c.244_246</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Hepatic artery enlargement</td>
<td></td>
<td></td>
<td></td>
<td>del ACC</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>FNH</td>
<td></td>
<td></td>
<td></td>
<td>p.T82del</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Intrapancreatic AVM</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Ileal AVM</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>AVM</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Caecal AVM</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Uterine AVM</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>49</td>
<td>M</td>
<td>1</td>
<td>No pathological findings</td>
<td>2.28</td>
<td>6.38</td>
<td>23.4%</td>
<td>Exon 3:</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>change</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>229T&gt;C</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Cys77Arg</td>
</tr>
<tr>
<td>3</td>
<td>41</td>
<td>F</td>
<td>3</td>
<td>Intrahepatic telangiectasias</td>
<td>3.12</td>
<td>2.93</td>
<td>4.4%</td>
<td>Exon 10:</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Hepatic AV shunt</td>
<td></td>
<td></td>
<td></td>
<td>change</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1436G&gt;C</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Arg479Pro</td>
</tr>
<tr>
<td>No</td>
<td>Age</td>
<td>Gender</td>
<td>Gender</td>
<td>Hepatomegaly</td>
<td>Exon 10:</td>
<td>Percent</td>
<td>Exon 10:</td>
<td></td>
</tr>
<tr>
<td>----</td>
<td>-----</td>
<td>--------</td>
<td>--------</td>
<td>--------------</td>
<td>---------</td>
<td>---------</td>
<td>---------</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>70</td>
<td>F</td>
<td>0</td>
<td>Hepatomegaly</td>
<td>3.7</td>
<td>6.59</td>
<td>24.2%</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1436G&gt;C</td>
<td>Arg479Pro</td>
<td>*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>49</td>
<td>M</td>
<td>0</td>
<td>Intrahepatic</td>
<td>2.9</td>
<td>4.57</td>
<td>13.5%</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>telangiectasias</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1436G&gt;C</td>
<td>Arg479Pro</td>
<td>*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>51</td>
<td>M</td>
<td>1</td>
<td>Hepatomegaly</td>
<td>3.3</td>
<td>6.05</td>
<td>16.4%</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1436G&gt;C</td>
<td>Arg479Pro</td>
<td>*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male (M) or Female (F)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-----------------------</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>ESS</strong>: Epistaxis Severity Score</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Epistaxis frequency</strong>: Daily (D) or weekly (W)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>TTE</strong>: Transthoracic echocardiography</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>CI</strong>: Cardiac Index on TTE</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>NRH</strong>: Nodular regenerative hyperplasia</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>FNH</strong>: Focal nodular hyperplasia</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>AVM</strong>: Arteriovenous malformation</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>AV shunt</strong>: Arteriovenous shunt (hepatic artery to hepatic vein)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>AP shunt</strong>: Arterioportal shunt (hepatic artery to portal vein)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Patient 4 is the mother of patient 3
Figure 1

A. P5-Retinas

B. Vein

C. P7-Retinas

D. Vein

E. P9-Retinas

F. Vein

WT ALK1 +/-

P5-Retinas

A

P7-Retinas

25

12.5

0

Vessel width (µm)

****
p=0.05115

10

5

0

No. branch points / 104 µm2

10

5

0

No. branch points / 104 µm2

Vein

Artery

WT ALK1 +/

Vein

Artery

WT ALK1 +/

Vein

Artery

WT ALK1 +/

Vein

Artery

WT ALK1 +/
Figure 1. Heterozygous loss of ALK1 results in retinal vascular hyperplasia.

(A) Whole-mount visualization of blood vessels by isolectin B4 staining of wild type (WT) or ALK1<sup>+/−</sup> mice at P5. Red and green islets show venous and arterial selected regions where quantification analysis was done. A indicates artery and V indicates vein. (B) Quantification of vessel width and number of branch points in veins and arteries of wild-type (n=8) and ALK1<sup>+/−</sup> (n=7) retinas at P5. (C) Whole-mount visualization of blood vessels by isolectin B4 staining of wild type (WT) or ALK1<sup>+/−</sup> mice at P7. (D) Quantification of vessel width and number of branch points in veins and arteries of wild-type (n=28) and ALK1<sup>+/−</sup> (n=27) retinas at P7. (E) Whole-mount visualization of blood vessels by isolectin B4 staining of wild type (WT) or ALK1<sup>+/−</sup> mice at P9. (F) Quantification of vessel width and number of branch points in veins and arteries of wild-type (n≥3) and ALK1<sup>+/−</sup> (n=10) retinas at P9. Error bars indicate the standard error of the mean. Statistical significance of two-tailed Mann-Whitney U tests: **, p<0.01; ***, p<0.001; ****, p<0.0001.
Figure 2

A  
WT ALK1+/−

B  
Control(BMP9+VEGF)  
BMP9+ VEGF

C  
Control(BMP9+VEGF)  
BMP9+ VEGF

D  
Cell Number (x 10⁴)

E  
BrdU positive cells / total cells (%)

First line  
WT ALK1−/−  
WT ALK1+/−

Second line  
WT ALK1−/−  
WT ALK1+/−
Figure 2. ALK1 negatively regulates endothelial cell proliferation in vitro and in vivo.

(A) Representative images of wild-type and $ALKI^{+/}$ retinas immunostained with Erg-1/2/3 (green), Edu (blue) and isolectin B4 (red). Lines indicate the separation (20 µm) between the two areas of quantification: first line (tip and first neighboring cells) and second line (second and third neighboring cells). Scale bars, 20 µm. Yellow and white asterisks indicate Erg- and Edu-positive cells respectively located on the second line. (B) Bars show quantification of endothelial nuclei per unit area assessed by Erg positivity in wild-type (n=11) and $ALKI^{+/}$ (n=6) retinas at P7. (C) Quantification of percentage of proliferative endothelial cells (double Edu+/Erg+ with respect to total Erg+) in wild-type (n=11) and $ALKI^{+/}$ (n=6) retinas at P7. (D) HUVECs were incubated for 48 h or 72 h in medium 199 with 0.5% serum, in the presence or absence of 10 ng/ml VEGF, 10 ng/ml BMP9 or 10 ng/ml VEGF and 10 ng/ml BMP9, after which the cell number was counted. Each data point represents the mean of at least three independent experiments. (E) Bars show quantification of proliferation of quiescent HUVECs plated for 24 h in the absence or presence of 10 ng/ml VEGF, 10 ng/ml BMP9 or 10 ng/ml VEGF and 10 ng/ml BMP9, or exponential HUVECs (with 20% FCS) plated for 24 h in the absence or presence of 0.5 µM LDN-212854 and in the absence or presence of 10 ng/ml BMP9. Cells were pulsed with BrdU for 4 h and subjected to immunostaining analysis. Results shown are the means of four independent experiments. Error bars indicate the standard errors of the mean. Statistical significance of two-tailed Mann-Whitney U tests: *, p<0.05; **, p<0.01; ***, p<0.001.
Figure 3. BMP9 inhibits VEGF-mediated activation of AKT and ERK.

(A) Growth factor-depleted HUVECs were pretreated with vehicle or 10 ng/ml BMP9 for 4 h, stimulated with VEGF for 30 min, and immunoblotted using the indicated antibodies. A representative blot of 5 independent experiments is shown. (B) Bars show quantification of the relative immunoreactivity of phosphoVEGFR2 normalized with respect to total VEGFR2. The mean of five independent experiments is shown. (C) Bars show quantification of the relative immunoreactivity of phosphoAKT (Ser473) normalized with respect to total AKT assessed as the mean of five independent experiments. (D) Bars show quantification of the relative immunoreactivity of phosphoERK1/2 normalized with respect to total ERK1/2. The mean of five independent experiments is shown. (E) Bars show quantification of the relative immunoreactivity of phosphoSMAD1/5 normalized with respect to total SMAD1/5. The mean of five independent experiments is shown. (F) Bars show quantification of the relative immunoreactivity of phospho-p38MAPK normalized with respect to total p38 MAPK. The mean of five independent experiments is shown. Error bars indicate the standard errors of the mean. Statistical significance of two-tailed Mann-Whitney U tests: *, p<0.05; **, p<0.01.
Figure 4

A

PTEN Activity (% of PI(3,4,5)P3 converted)

4 h BMP9 Pretreatment
VEGF 30'

B

Protein

PTEN / Tubulin (% of basal)

BMP9-4h  BMP9-24h

C

mRNA

PTEN / RPL32 (% of basal)

BMP9-4h  BMP9-24h

D

Unrelated siRNA  PTEN siRNA

E

Number of cells (% of control)

Unrelated siRNA  PTEN siRNA

F

Number of cells (% of control)

DMSO  PTEN inhibitor
Figure 4. BMP9 effects are mediated by PTEN.

(A) Growth factor-depleted HUVECs were pretreated with vehicle or 10 ng/ml BMP9 for 4 h and stimulated or not with VEGF for 30 min. Cells were lysed, PTEN immunoprecipitated and PTEN phosphatase activity measured by evaluating the conversion of PI(3,4,5)₃ to PI(4,5)₂ by ELISA. Results are expressed as the percentage conversion of initial PI(3,4,5)₃ to PI(4,5)₂. The mean of four independent experiments is shown. (B) Growth factor-depleted HUVECs were treated with vehicle or 10 ng/ml BMP9 for 4 or 24 h and immunoblotted using appropriated antibodies. Bars show quantification of PTEN protein amount in basal situation (n=10) or induced by BMP9 4 h (n=5) or 24 h (n=10) and normalized with respect to tubulin. (C) Bars show quantification of PTEN mRNA induced by BMP9 stimulation for 4 or 24 h and normalized with respect to RPL32 gene. The mean of four independent experiments is shown. (D) HUVECs were transiently transfected with an unrelated control siRNA (unrelated siRNA) or PTEN siRNA, as described. After 48 h, cells were depleted of growth factors for 16 h. Cells were pretreated or not with 10 ng/ml BMP9 for 4 h, and then stimulated for 30 min in the absence or presence of 10 ng/ml VEGF. Cells were lysed and immunoblotted using the indicated antibodies. A representative blot of five independent experiments is shown. (E) After transfection with siRNAs, 1 x 10⁴ cells were seeded in 24-well plastic plates in normal medium. The next day the medium was changed to M199 with 0.5% FCS and the cells were treated or not with 10 ng/ml BMP9, 10 ng/ml of VEGF or a combination of BMP9 and VEGF. After 48 h the cell number was assessed. Each data point represents the mean of at least eight independent experiments. (F) HUVECs were incubated in medium 199 with 0.5% serum, in the presence or absence of 10 ng/ml VEGF, 10 ng/ml BMP9, 10 ng/ml VEGF and 10 ng/ml BMP9, and in the absence or presence of 0.5 µM SF1670 PTEN inhibitor. After 72 h the cell number was counted. Each data point represents the mean of at least four independent experiments. Error bars indicate the standard errors of the mean. Statistical significance of two-tailed Mann-Whitney U tests: *, p<0.05; **, p<0.01; ***, p<0.001.
Figure 5

A

Hallmark PI3K-AKT-MTOR signaling

P < 0.001

Enrichment score

Rank in ordered dataset

Telangiectasia Normal
HHT2 tissue Expression difference (t-statistic)

PID PI3KCI-AKT

P = 0.002

Enrichment score

Rank in ordered dataset

Telangiectasia Normal
HHT2 tissue Expression difference (t-statistic)

Oncogenic PI3KCA mutation signature

P < 0.001

Enrichment score

Rank in ordered dataset

Telangiectasia Normal
HHT2 tissue Expression difference (t-statistic)

B

CD34 pNDRG1 pS6 pAKT Ki67

Control HHT2 patient 5 Control

C

D

E

F

% of pAKT positive vessels

% of pNDRG1 positive vessels

% of pS6 positive endothelial cells

% of proliferative endothelial cells

Control HHT2 patients

Control HHT2 patients

Control HHT2 patients

Control HHT2 patients

*
Figure 5. Increased activation of PI3K signaling and endothelial cell proliferation in HHT2 cutaneous telangiectasia biopsies.

(A) GSEA output plots showing significant over-expression of genes sets corresponding to PI3K-AKT-mTOR canonical annotations (Hallmark PI3K-AKT-MTOR signaling and PID PI3KCI-AKT) or genes significantly over-expressed by oncogenic PI3KCA mutations. The detailed results of each set are provided in Supplementary Table 1. The GSEA enrichment scores and the nominal $P$ values are shown. The red-shadow areas mark the leading peaks that contribute to the associations. (B) CD34, pNDRG1, pS6, pAKT and Ki-67 (brown nuclei, arrows) staining of a control and a HHT2 patient. Scale bars, 100 µm (C) Quantification of the percentage of pAKT-positive vessels in controls (n=3) and HHT2 patients (n=5). (D) Quantification of the percentage of pNDRG1-positive vessels in controls (n=3) and HHT2 patients (n=6). (E) Quantification of the percentage of pS6-positive endothelial cells in controls (n=3) and HHT2 patients (n=5). (F) Quantification of the percentage of Ki-67-positive endothelial cells in controls (n=3) and HHT2 patients (n=6). Error bars indicate the standard errors of the mean. Statistical significance of two-tailed Mann-Whitney U tests: *, $p<0.05$. 
Figure 6

A

WT ALK1 +/-

p110α KD/WT ALK1 +/- : p110α KD/WT

Vessel width (µm)

WT ALK1 +/-

**

Vehicle PI3Ki

* P0 P6 (6:00pm) P7 (10:00am) P7 (2:00pm) PI3Ki PI3Ki Isolation

D

WT Vehicle ALK1 +/- Vehicle

PI3Ki

E

Vessel width (µm)

WT ALK1 +/- WT ALK1 +/-

Vehicle PI3Ki
Figure 6. In vivo inhibition of PI3K blocks vascular hyperplasia in ALKI^{+/−} retinas.

(A) Whole-mount visualization of blood vessels by isolectin B4 staining wild-type, ALKI^{+/−}, p110α^{KD/WT} and double ALKI^{+/−}/p110α^{KD/WT} retinas at P7. (B) Quantification of vessel width in veins of wild-type (n=4), ALKI^{+/−} (n=8), p110α^{KD/WT} (n=4) and double ALKI^{+/−}/p110α^{KD/WT} (n=6) retinas. (C) Scheme of pharmacologic approach to inhibit PI3K with LY294002. (D) Isolectin B4 stained wild-type and ALKI^{+/−} treated with vehicle or LY294002 at P6 and P7. (E) Quantification of the vessel width of retinas shown in C (n≥4 per treatment and genotype). Error bars indicate the standard errors of the mean. Statistical significance of two-tailed Mann-Whitney U tests: *, p<0.05; **, p<0.01.